表紙
市場調查報告書

真性多血症 (PV) - 流行病學預測:2030年

Polycythemia Vera - Epidemiology Forecast to 2030

出版商 DelveInsight Business Research LLP 商品編碼 948135
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
真性多血症 (PV) - 流行病學預測:2030年 Polycythemia Vera - Epidemiology Forecast to 2030
出版日期: 2020年06月01日內容資訊: 英文 100 Pages
簡介

2017年真性多血症 (PV) 和確診的患病人數,在主要7個國家,是283,442人。美國,是157,290人。歐洲5個國家,在德國最大是14,502人,接著是法國、英國。在日本,是18,954人。

本報告提供真性多血症 (PV) 調查分析,疾病概要, (德國,西班牙,義大利,法國,英國) 、日本的患者族群相關考察相關的系統性資訊。流行病學,美國、歐洲5個國家

目錄

第1章 主要考察

第2章 真性多血症 (PV)的摘要整理

第3章 真性多血症 (PV) :疾病的背景和概要

  • 簡介
  • 徵兆與症狀
  • 病理生理學
  • 危險因素
  • 診斷

第4章 病人旅程

第5章 流行病學和患者族群

  • 流行病學的主要調查結果
  • 前提條件與根據:主要7個國家
  • 流行病學方案:主要7個國家
  • 美國的流行病學
  • 歐洲5個國家的各國流行病學
    • 德國的流行病學
    • 法國的流行病學
    • 義大利的流行病學
    • 西班牙的流行病學
    • 英國的流行病學
  • 日本的流行病學

第6章 治療流程,目前治療,診療

  • 真性多血症 (PV)的治療與管理
  • 真性多血症 (PV)的治療流程

第7章 KOL的見解

第8章 未滿足需求

第9章 附錄

第10章 DelveInsight的服務內容

第11章 免責聲明

第12章 關於DelveInsight

目錄
Product Code: DIEI0772

DelveInsight's 'Polycythemia Vera (PV)-Epidemiology Forecast-2030' report delivers an in-depth understanding of the PV, historical and forecasted epidemiology as well as the PV trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Polycythemia Vera (PV) Disease Understanding

Polycythemia Vera (PV) is a condition characterized by an increased number of red blood cells in the bloodstream (erythrocytosis) and affected people may also have excess white blood cells and platelets. Most cases of PV are not inherited and are acquired during a person's lifetime

PV is diagnosed by testing the blood for levels of a hormone called erythropoietin as well as testing the blood for mutations in JAK2 or TET2. If mutations are not found in the red blood cells but the doctors still suspect a diagnosis of polycythemia vera, a bone marrow biopsy may be done to look for mutations in the hematopoietic blood cells which are located in the bone marrow.

The most precarious symptom of polycythemia vera is the chance for a thrombotic event that can cause a heart attack or stroke. There is also a small chance that polycythemia vera could cause an individual to develop leukemia. With proper treatment, however, these symptoms have not been shown to greatly affect the expected lifespan of a person with polycythemia vera. Another complication i.e. itching (pruritus) patients can manage with the help of various medicines.

Polycythemia Vera (PV) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of PV, Prevalence Population of PV Based on Symptoms, Gender-specific Symptomatic Prevalence of PV, Age-specific Symptomatic Prevalence of PV, Prevalence of PV Based on Risk, and Prevalence of PV by Gene Mutation scenario of PV in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.

Polycythemia Vera (PV) Detailed Epidemiology Segmentation

  • The total prevalent population of PV in the 7MM was 283,442 in 2017.
  • The estimates show the highest prevalence of PV in the United States with 157,290 cases in 2017.
  • DelveInsight's epidemiology model for PV estimates that out of the total population of 157,290 cases in the US for PV, 62,916 cases and 94,374 cases were contributed by asymptomatic and symptomatic, respectively.
  • Among the European five countries, Germany had the highest symptomatic prevalent population of PV with 14,502 cases, followed by France and the United Kingdom. Japan had 18,954 symptomatic prevalent cases for PV in 2017.
  • As per the analysis, a higher percentage of prevalence was observed for males, in comparison to females, in all the 7MM countries. Out of the total symptomatic population in the US for PV, 61,060 cases and 33,314 cases were contributed by males and females in 2017.
  • It has been also observed that PV in the US is mostly prevalent in the age group of >75 years.
  • A total of 94,374 diagnosed (symptomatic) prevalent population of PV was assessed in 2017. Out of these cases, ~87,881 cases of PV were calculated for patients with JAK2 V617F, thereby accounting for the highest number of cases with gene mutation with ~97% of total PV cases with JAK2 mutation.
  • Around 23% of patients accounted for low-risk categories, and 77% accounted for high-risk cases in 2017 in the United States.

Scope of the Report:

  • The report covers the descriptive overview of PV, explaining its causes, signs and symptoms, complications, clinical aspects, and pathophysiology.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of PV.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Population of PV, Prevalence Population of PV Based on Symptoms, Gender-specific Symptomatic Prevalence of PV, Age-specific Symptomatic Prevalence of PV, Prevalence of PV Based on Risk, and Prevalence of PV by Gene Mutation.

Report Highlights:

  • 11-Year Forecast of PV
  • 7MM Coverage
  • Total Prevalent Population of PV
  • Prevalence Population of PV Based on Symptoms
  • Gender-specific Symptomatic Prevalence of PV
  • Age-specific Symptomatic Prevalence of PV
  • Prevalence of PV Based on Risk
  • Prevalence of PV by Gene Mutation

Key Questions Answered

  • What is the disease risk, burden and unmet needs of PV?
  • What is the historical PV patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of PV at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to PV?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of PV during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Reasons to buy:

The PV report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM PV epidemiology forecast.
  • The PV epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The PV epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Table of Contents

1. Key Insights

2. Executive Summary of Polycythemia Vera

3. Polycythemia Vera: Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. Polycythemia Vera Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. Polycythemia Vera Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. Polycythemia Vera Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. Polycythemia Vera Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. Polycythemia Vera Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. Polycythemia Vera Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. Polycythemia Vera Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. Polycythemia Vera Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. Polycythemia Vera Treatment and Management
  • 6.2. Polycythemia Vera Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

List of Tables

  • Table 1 Summary of Polycythemia Vera Epidemiology and Key Events (2017-2030)
  • Table 2 Thrombotic Complications in Polycythemia Vera
  • Table 3 Evidence statements and grades of recommendations
  • Table 4 Proposed modified criteria for the diagnosis of Polycythemia Vera
  • Table 5 Stage 1 and 2 investigations in patients with an absolute Erythrocytosis
  • Table 6 World Health Organization diagnostic criteria for Polycythemia Vera
  • Table 7 Recommended diagnostic criteria for Polycythemia Vera
  • Table 8 Total Prevalent Population of Polycythemia Vera in the 7MM (2017-2030)
  • Table 9 Total Prevalent Population of Polycythemia Vera in the US (2017-2030)
  • Table 10 Prevalent Population of Polycythemia Vera Based on Symptoms in the US (2017-2030)
  • Table 11 Gender-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in the US (2017-2030)
  • Table 12 Age-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in the US (2017-2030)
  • Table 13 Prevalence of Polycythemia Vera Based on Risk in the US (2017-2030)
  • Table 14 Prevalence of PV by Gene Mutation in the US (2017-2030)
  • Table 15 Total Prevalent Population of Polycythemia Vera in Germany (2017-2030)
  • Table 16 Prevalent Population of Polycythemia Vera Based on Symptoms in Germany (2017-2030)
  • Table 17 Gender-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in Germany (2017-2030)
  • Table 18 Age-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in Germany (2017-2030)
  • Table 19 Prevalence of Polycythemia Vera Based on Risk in Germany (2017-2030)
  • Table 20 Prevalence of PV by Gene Mutation in Germany (2017-2030)
  • Table 21 Total Prevalent Population of Polycythemia Vera in France (2017-2030)
  • Table 22 Prevalent Population of Polycythemia Vera Based on Symptoms in France (2017-2030)
  • Table 23 Gender-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in France (2017-2030)
  • Table 24 Age-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in France (2017-2030)
  • Table 25 Prevalence of Polycythemia Vera Based on Risk in France (2017-2030)
  • Table 26 Prevalence of PV by Gene Mutation in France (2017-2030)
  • Table 27 Total Prevalent Population of Polycythemia Vera in Italy (2017-2030)
  • Table 28 Prevalent Population of Polycythemia Vera Based on Symptoms in Italy (2017-2030)
  • Table 29 Gender-specific Diagnosed (symptomatic) Prevalence of Polycythemia Vera in Italy (2017-2030)
  • Table 30 Age-specific Diagnosed (symptomatic) Prevalence of Polycythemia Vera in Italy (2017-2030)
  • Table 31 Prevalence of Polycythemia Vera Based on Risk in Italy (2017-2030)
  • Table 32 Prevalence of PV by Gene Mutation in Italy (2017-2030)
  • Table 33 Total Prevalent Population of Polycythemia Vera in Spain (2017-2030)
  • Table 34 Prevalent Population of Polycythemia Vera (PV) Based on Symptoms in Spain (2017-2030)
  • Table 35 Gender-specific Prevalence of Polycythemia Vera in Spain (2017-2030)
  • Table 36 Age-specific Prevalence of Polycythemia Vera in Spain (2017-2030)
  • Table 37 Prevalence of Polycythemia Vera Based on Risk in Spain (2017-2030)
  • Table 38 Prevalence of PV by Gene Mutation in Spain (2017-2030)
  • Table 39 Total Prevalent Population of Polycythemia Vera in the United Kingdom (2017-2030)
  • Table 40 Prevalent Population of Polycythemia Vera (PV) Based on Symptoms in the UK (2017-2030)
  • Table 41 Gender-specific Prevalence of Polycythemia Vera in the UK (2017-2030)
  • Table 42 Age-specific Prevalence of Polycythemia Vera in the UK (2017-2030)
  • Table 43 Prevalence of Polycythemia Vera Based on Risk in the UK (2017-2030)
  • Table 44 Prevalence of PV by Gene Mutation in the UK (2017-2030)
  • Table 45 Total Prevalent Population of Polycythemia Vera in Japan (2017-2030)
  • Table 46 Prevalent Population of Polycythemia Vera (PV) Based on Symptoms in Japan (2017-2030)
  • Table 47 Gender-specific Prevalence of Polycythemia Vera in Japan (2017-2030)
  • Table 48 Age-specific Prevalence of Polycythemia Vera in Japan (2017-2030)
  • Table 49 Prevalence of Polycythemia Vera Based on Risk in Japan (2017-2030)
  • Table 50 Prevalence of PV by Gene Mutation in Japan (2017-2030)

List of Figures

  • Figure 1 Types of Myeloproliferative Neoplasm (MPN)
  • Figure 2 Classification of Polycythemia
  • Figure 3 Affected areas and associated symptoms
  • Figure 4 Risk factors of PV
  • Figure 5 Schematic representation of the Epo-mediated signaling pathway
  • Figure 6 JAK/STAT Pathway in MPN
  • Figure 7 Scheme of the IGF-I/IGFBP-1-induced intracellular pathway that leads to inhibition of apoptosis.
  • Figure 8 Structure of Janus Kinases
  • Figure 9 Impact of JAK2 V617F Allele
  • Figure 10 Histopathologic spectrum of two recognized stages of Polycythemia Vera
  • Figure 11 Diagnostic Methods
  • Figure 12 A modern diagnostic algorithm for suspected Polycythemia Vera
  • Figure 13 Changes in plasma or red cell volume in various states of polycythemia
  • Figure 14 Classification of the Absolute Erythrocytosis
  • Figure 15 Total Prevalent Population of Polycythemia Vera in the 7MM (2017-2030)
  • Figure 16 Total Prevalent Population of Polycythemia Vera in the US (2017-2030)
  • Figure 17 Prevalent Population of Polycythemia Vera Based on Symptoms in the US (2017-2030)
  • Figure 18 Gender-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in the US (2017-2030)
  • Figure 19 Age-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in the US (2017-2030)
  • Figure 20 Prevalence of Polycythemia Vera Based on Risk in the US (2017-2030)
  • Figure 21 Prevalence of PV by Gene Mutation in the US (2017-2030)
  • Figure 22 Total Prevalent Population of Polycythemia Vera in Germany (2017-2030)
  • Figure 23 Prevalent Population of Polycythemia Vera Based on Symptoms in Germany (2017-2030)
  • Figure 24 Gender-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in Germany (2017-2030)
  • Figure 25 Age-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in Germany (2017-2030)
  • Figure 26 Prevalence of Polycythemia Vera Based on Risk in Germany (2017-2030)
  • Figure 27 Prevalence of PV by Gene Mutation in Germany (2017-2030)
  • Figure 28 Total Prevalent Population of Polycythemia Vera in France (2017-2030)
  • Figure 29 Prevalent Population of Polycythemia Vera Based on Symptoms in France (2017-2030)
  • Figure 30 Gender-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in France (2017-2030)
  • Figure 31 Age-specific Diagnosed (Symptomatic) Prevalence of Polycythemia Vera in France (2017-2030)
  • Figure 32 Prevalence of Polycythemia Vera Based on Risk in France (2017-2030)
  • Figure 33 Prevalence of PV by Gene Mutation in France (2017-2030)
  • Figure 34 Total Prevalent Population of Polycythemia Vera in Italy (2017-2030)
  • Figure 35 Prevalent Population of Polycythemia Vera Based on Symptoms in Italy (2017-2030)
  • Figure 36 Gender-specific Diagnosed (symptomatic) Prevalence of Polycythemia Vera in Italy (2017-2030)
  • Figure 37 Age-specific Diagnosed (symptomatic) Prevalence of Polycythemia Vera in Italy (2017-2030)
  • Figure 38 Prevalence of Polycythemia Vera Based on Risk in Italy (2017-2030)
  • Figure 39 Prevalence of PV by Gene Mutation in Italy (2017-2030)
  • Figure 40 Total Prevalent Population of Polycythemia Vera in Spain (2017-2030)
  • Figure 41 Prevalent Population of Polycythemia Vera Based on Symptoms in Spain (2017-2030)
  • Figure 42 Gender-specific Prevalence of Polycythemia Vera in Spain (2017-2030)
  • Figure 43 Age-specific Prevalence of Polycythemia Vera in Spain (2017-2030)
  • Figure 44 Prevalence of Polycythemia Vera Based on Risk in Spain (2017-2030)
  • Figure 45 Prevalence of PV by Gene Mutation in Spain (2017-2030)
  • Figure 46 Total Prevalent Population of Polycythemia Vera in the United Kingdom (2017-2030)
  • Figure 47 Total Prevalent Population of PV Based on Symptoms in the UK (2017-2030)
  • Figure 48 Gender-specific Prevalence of Polycythemia Vera in the UK (2017-2030)
  • Figure 49 Age-specific Prevalence of Polycythemia Vera in the UK (2017-2030)
  • Figure 50 Prevalence of Polycythemia Vera Based on Risk in the UK (2017-2030)
  • Figure 51 Prevalence of PV by Gene Mutation in the UK (2017-2030)
  • Figure 52 Total Prevalent Population of Polycythemia Vera in Japan (2017-2030)
  • Figure 53 Prevalent Population of Polycythemia Vera (PV) Based on Symptoms in Japan (2017-2030)
  • Figure 54 Gender-specific Prevalence of Polycythemia Vera in Japan (2017-2030)
  • Figure 55 Age-specific Prevalence of Polycythemia Vera PV in Japan (2017-2030)
  • Figure 56 Prevalence of Polycythemia Vera Based on Risk in Japan (2017-2030)
  • Figure 57 Prevalence of PV by Gene Mutation in Japan (2017-2030)